

Martin Lagging

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6221535/publications.pdf>

Version: 2024-02-01

113
papers

4,872
citations

136950

32
h-index

98798

67
g-index

113
all docs

113
docs citations

113
times ranked

5084
citing authors

#	ARTICLE	IF	CITATIONS
1	A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. <i>Liver International</i> , 2011, 31, 30-60.	3.9	333
2	Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. <i>Lancet, The</i> , 2015, 385, 1075-1086.	13.7	281
3	Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. <i>Journal of Hepatology</i> , 2002, 37, 837-842.	3.7	245
4	Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 396-415.	8.1	237
5	Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 325-336.	8.1	208
6	Interferon (IFN)â€“Inducible Proteinâ€“10: Association with Histological Results, Viral Kinetics, and Outcome during Treatment with Pegylated IFNâ€“2a and Ribavirin for Chronic Hepatitis C Virus Infection. <i>Journal of Infectious Diseases</i> , 2006, 194, 895-903.	4.0	201
7	Randomized comparison of 12 or 24 weeks of peginterferon Î±-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. <i>Hepatology</i> , 2008, 47, 1837-1845.	7.3	196
8	IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. <i>Hepatology</i> , 2006, 44, 1617-1625.	7.3	193
9	Interobserver study of liver histopathology using the Ishak score in patients with chronic hepatitis C virus infection. <i>Liver International</i> , 1999, 19, 183-187.	3.9	182
10	International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2005, 43, 250-257.	3.7	143
11	Response Prediction in Chronic Hepatitis C by Assessment of IP-10 and IL28B-Related Single Nucleotide Polymorphisms. <i>PLoS ONE</i> , 2011, 6, e17232.	2.5	131
12	Moderate alcohol intake increases fibrosis progression in untreated patients with hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2002, 9, 235-241.	2.0	128
13	Cirrhosis in hepatitis C virus-infected patients can be excluded using an index of standard biochemical serum markers. <i>Scandinavian Journal of Gastroenterology</i> , 2005, 40, 867-872.	1.5	127
14	Surveillance of wastewater revealed peaks of SARS-CoV-2 preceding those of hospitalized patients with COVID-19. <i>Water Research</i> , 2021, 189, 116620.	11.3	112
15	Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C. <i>Hepatology</i> , 2010, 51, 1523-1530.	7.3	105
16	IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C. <i>Journal of Hepatology</i> , 2011, 55, 980-988.	3.7	97
17	Functional Role of Hepatitis C Virus Chimeric Glycoproteins in the Infectivity of Pseudotyped Virus. <i>Journal of Virology</i> , 1998, 72, 3539-3546.	3.4	97
18	Diagnostic Performance of Five Assays for Anti-Hepatitis E Virus IgG and IgM in a Large Cohort Study. <i>Journal of Clinical Microbiology</i> , 2016, 54, 549-555.	3.9	94

#	ARTICLE	IF	CITATIONS
19	IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 33, 1162-1172.	3.7	83
20	Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C. <i>Hepatology</i> , 2010, 52, 430-435.	7.3	82
21	Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: A randomized phase II trial. <i>Journal of Hepatology</i> , 2006, 45, 539-546.	3.7	76
22	Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection. <i>Journal of Viral Hepatitis</i> , 2007, 14, 29-35.	2.0	70
23	Progression of fibrosis in untreated patients with hepatitis C virus infection. <i>Liver</i> , 2002, 22, 136-144.	0.1	69
24	HCV-Specific T-Cell Response in Relation to Viral Kinetics and Treatment Outcome (DITTO-HCV Project). <i>Gastroenterology</i> , 2007, 133, 1132-1143.	1.3	57
25	Ribavirin: pharmacology, multiple modes of action and possible future perspectives. <i>Future Virology</i> , 2019, 14, 153-160.	1.8	53
26	IL28B polymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon/ribavirin for chronic hepatitis C genotype 1. <i>Journal of Viral Hepatitis</i> , 2011, 18, e325-31.	2.0	52
27	Peptide immunogen mimicry of putative E1 glycoprotein-specific epitopes in hepatitis C virus. <i>Journal of Virology</i> , 1994, 68, 4420-4426.	3.4	47
28	Interleukin 28B Gene Variation at rs12979860 Determines Early Viral Kinetics During Treatment in Patients Carrying Genotypes 2 or 3 of Hepatitis C Virus. <i>Journal of Infectious Diseases</i> , 2011, 203, 1748-1752.	4.0	45
29	Complement-Mediated Enhancement of Antibody Function for Neutralization of Pseudotype Virus Containing Hepatitis C Virus E2 Chimeric Glycoprotein. <i>Journal of Virology</i> , 2002, 76, 2150-2158.	3.4	43
30	Nosocomial Transmission of HCV in a Cardiology Ward During the Window Phase of Infection: An Epidemiological and Molecular Investigation. <i>Scandinavian Journal of Infectious Diseases</i> , 2002, 34, 580-582.	1.5	38
31	Variants of the inosine triphosphate pyrophosphatase gene are associated with reduced relapse risk following treatment for HCV genotype 2/3. <i>Hepatology</i> , 2014, 59, 2131-2139.	7.3	38
32	Core mutations, IL28B polymorphisms and response to peginterferon/ribavirin treatment in Swedish patients with hepatitis C virus genotype 1 infection. <i>BMC Infectious Diseases</i> , 2011, 11, 124.	2.9	37
33	Impact of IL28B-Related Single Nucleotide Polymorphisms on Liver Histopathology in Chronic Hepatitis C Genotype 2 and 3. <i>PLoS ONE</i> , 2012, 7, e29370.	2.5	32
34	Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled study. <i>BMC Gastroenterology</i> , 2012, 12, 11.	2.0	30
35	A non-invasive fibrosis score predicts treatment outcome in chronic hepatitis C virus infection. <i>Scandinavian Journal of Gastroenterology</i> , 2008, 43, 73-80.	1.5	29
36	The case for simplifying and using absolute targets for viral hepatitis elimination goals. <i>Journal of Viral Hepatitis</i> , 2021, 28, 12-19.	2.0	28

#	ARTICLE	IF	CITATIONS
37	Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections – A Scandinavian real-life study. <i>PLoS ONE</i> , 2017, 12, e0179764.	2.5	28
38	IP-10 predicts the first phase decline of HCV RNA and overall viral response to therapy in patients co-infected with chronic hepatitis C virus infection and HIV. <i>Scandinavian Journal of Infectious Diseases</i> , 2010, 42, 896-901.	1.5	27
39	Comparison of Serum Hepatitis C Virus RNA and Core Antigen Concentrations and Determination of Whether Levels Are Associated with Liver Histology or Affected by Specimen Storage Time. <i>Journal of Clinical Microbiology</i> , 2002, 40, 4224-4229.	3.9	26
40	Chronic Hepatitis C in Sweden: Genotype Distribution Over Time in Different Epidemiological Settings. <i>Scandinavian Journal of Infectious Diseases</i> , 1999, 31, 355-358.	1.5	25
41	Evaluation of QuickVue, a rapid enzyme immunoassay test for the detection of serum antibodies to <i>Helicobacter pylori</i> . <i>Diagnostic Microbiology and Infectious Disease</i> , 1993, 16, 317-320.	1.8	24
42	Ribavirin plasma concentration is a predictor of sustained virological response in patients treated for chronic hepatitis C virus genotype 2/3 infection. <i>Journal of Viral Hepatitis</i> , 2011, 18, 245-251.	2.0	24
43	Impact of IL28B, ITPA and PNPLA3 genetic variants on therapeutic outcome and progression of hepatitis C virus infection. <i>Pharmacogenomics</i> , 2015, 16, 1179-1188.	1.3	24
44	Imported Case of Lassa Fever in Sweden With Encephalopathy and Sensorineural Hearing Deficit. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw198.	0.9	23
45	Impact of IL28B-Related Single Nucleotide Polymorphisms on Liver Transient Elastography in Chronic Hepatitis C Infection. <i>PLoS ONE</i> , 2013, 8, e80172.	2.5	22
46	Neutralization of Pseudotyped Vesicular Stomatitis Virus Expressing Hepatitis C Virus Envelope Glycoprotein 1 or 2 by Serum from Patients. <i>Journal of Infectious Diseases</i> , 2002, 185, 1165-1169.	4.0	21
47	Treatment of hepatitis C virus infection: Updated Swedish Consensus recommendations. <i>Scandinavian Journal of Infectious Diseases</i> , 2009, 41, 389-402.	1.5	21
48	PNPLA 3I148M genetic variant associates with insulin resistance and baseline viral load in HCV genotype 2 but not in genotype 3 infection. <i>BMC Medical Genetics</i> , 2012, 13, 82.	2.1	21
49	The novel <i>rs469415590</i> variant predicts virological response to therapy in patients with chronic hepatitis C virus type 1 infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 322-330.	3.7	21
50	Treatment of hepatitis C virus infection for adults and children: updated Swedish consensus guidelines 2017. <i>Infectious Diseases</i> , 2018, 50, 569-583.	2.8	20
51	Delayed Treatment of Pulmonary Blastomycosis Causing Vertebral Osteomyelitis, Paraspinal Abscess, and Spinal Cord Compression. <i>Scandinavian Journal of Infectious Diseases</i> , 1994, 26, 111-115.	1.5	19
52	PRO-C3: a new and more precise collagen marker for liver fibrosis in patients with chronic hepatitis C. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 83-87.	1.5	19
53	Impact of Obesity on the Bioavailability of Peginterferon- α 2a and Ribavirin and Treatment Outcome for Chronic Hepatitis C Genotype 2 or 3. <i>PLoS ONE</i> , 2012, 7, e37521.	2.5	19
54	Deficiency of SARS-CoV-2 T-cell responses after vaccination in long-term allo-HSCT survivors translates into abated humoral immunity. <i>Blood Advances</i> , 2022, 6, 2723-2730.	5.2	19

#	ARTICLE	IF	CITATIONS
55	High seroprevalence against hepatitis E virus in patients with chronic hepatitis C virus infection. <i>Journal of Clinical Virology</i> , 2017, 88, 39-45.	3.1	18
56	Inosine Triphosphate Pyrophosphatase Dephosphorylates Ribavirin Triphosphate and Reduced Enzymatic Activity Potentiates Mutagenesis in Hepatitis C Virus. <i>Journal of Virology</i> , 2018, 92, .	3.4	18
57	Response Prediction and Treatment Tailoring for Chronic Hepatitis C Virus Genotype 1 Infection. <i>Journal of Clinical Microbiology</i> , 2007, 45, 2439-2445.	3.9	16
58	A Model Explaining the Correlations Between IL28B-Related Genotypes, Hepatitis C Virus Genotypes, and Viral RNA Levels. <i>Gastroenterology</i> , 2010, 139, 1794-1796.	1.3	15
59	Retreatment with peg-interferon and ribavirin in patients with chronic hepatitis C virus genotype 2 or 3 infection with prior relapse. <i>Scandinavian Journal of Gastroenterology</i> , 2013, 48, 839-847.	1.5	15
60	Reduced immunogenicity of a third COVID-19 vaccination among recipients of allogeneic hematopoietic stem cell transplantation. <i>Haematologica</i> , 2022, 107, 1479-1482.	3.5	15
61	Grazoprevir plus peginterferon and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infection: a randomized trial. <i>Journal of Viral Hepatitis</i> , 2016, 23, 80-88.	2.0	14
62	Treatment of hepatitis C virus infection: updated Swedish Guidelines 2016. <i>Infectious Diseases</i> , 2017, 49, 561-575.	2.8	14
63	Impaired SARS-CoV-2-specific T-cell reactivity in patients with cirrhosis following mRNA COVID-19 vaccination. <i>JHEP Reports</i> , 2022, 4, 100496.	4.9	14
64	Immunoregulatory role of secreted glycoprotein G from respiratory syncytial virus. <i>Virus Research</i> , 2001, 75, 147-154.	2.2	13
65	Weight-adjusted dosing of ribavirin and importance of hepatitis C virus RNA below 1000 IU/mL by day 7 in short-term peginterferon therapy for chronic genotype 2/3 hepatitis C virus infection. <i>Hepatology</i> , 2008, 48, 695-695.	7.3	13
66	Treatment of hepatitis C virus infection in adults and children: Updated Swedish consensus recommendations. <i>Scandinavian Journal of Infectious Diseases</i> , 2012, 44, 502-521.	1.5	13
67	Short interferon and ribavirin treatment for HCV genotype 2 or 3 infection: NORDynamic trial and real-life experience. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 337-343.	1.5	13
68	Indeterminate third-generation hepatitis C recombinant immunoblot assay and HCV RNA analysis: Isolated reactivity against NS5 associated with HCV viraemia in clinical patients but not blood donors. <i>Scandinavian Journal of Infectious Diseases</i> , 2005, 37, 488-492.	1.5	12
69	Impact of Soluble CD26 on Treatment Outcome and Hepatitis C Virus-Specific T Cells in Chronic Hepatitis C Virus Genotype 1 Infection. <i>PLoS ONE</i> , 2013, 8, e56991.	2.5	12
70	Treatment of hepatitis C virus infection for adults and children: Updated Swedish consensus recommendations. <i>Infectious Diseases</i> , 2016, 48, 251-261.	2.8	12
71	Prevalence and comorbidities of chronic hepatitis C: a nationwide population-based register study in Sweden. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 61-68.	1.5	12
72	Sofosbuvir/velpatasvir for the treatment of HCV: excellent results from a phase-3, open-label study in Russia and Sweden. <i>Infectious Diseases</i> , 2019, 51, 131-139.	2.8	12

#	ARTICLE	IF	CITATIONS
73	Hepatitis C treatment response kinetics and impact of baseline predictors. <i>Journal of Viral Hepatitis</i> , 2011, 18, 400-407.	2.0	11
74	Chronic hepatitis E infection with an emerging virus strain in a heart transplant recipient successfully treated with ribavirin: a case report. <i>Journal of Medical Case Reports</i> , 2015, 9, 180.	0.8	11
75	Treatment for chronic hepatitis C in a cohort of opiate substitution therapy recipients in three Swedish cities – completion rates and efficacy. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 523-531.	1.6	10
76	Randomized Trial Evaluating the Impact of Ribavirin Mono-Therapy and Double Dosing on Viral Kinetics, Ribavirin Pharmacokinetics and Anemia in Hepatitis C Virus Genotype 1 Infection. <i>PLoS ONE</i> , 2016, 11, e0155142.	2.5	10
77	Look-back screening for the identification of transfusion-induced hepatitis C virus infection in Sweden. <i>Scandinavian Journal of Infectious Diseases</i> , 2011, 43, 522-527.	1.5	9
78	The impact of fibrosis and steatosis on early viral kinetics in HCV genotype 1 infected patients treated with PegIFN α 2a and ribavirin. <i>Journal of Viral Hepatitis</i> , 2012, 19, 488-496.	2.0	9
79	Hepatitis C elimination in Sweden: Progress, challenges and opportunities for growth in the time of COVID-19. <i>Liver International</i> , 2021, 41, 2024-2031.	3.9	9
80	Rapid Cytokine Release Assays for Analysis of Severe Acute Respiratory Syndrome Coronavirus 2-Specific T Cells in Whole Blood. <i>Journal of Infectious Diseases</i> , 2022, 226, 208-216.	4.0	9
81	Is HCV RNA analysis at day 7 cost-effective in deciding the duration of therapy in chronic HCV genotype 2/3 infection?. <i>Journal of Hepatology</i> , 2011, 54, 835-836.	3.7	8
82	Early quantification of HCV core antigen may help to determine the duration of therapy for chronic genotype 2 or 3 HCV infection. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2012, 31, 1631-1635.	2.9	8
83	Elevated antibody reactivity to measles virus N CORE protein among patients with multiple sclerosis and their healthy siblings with intrathecal oligoclonal immunoglobulin G production. <i>Journal of Clinical Virology</i> , 2014, 61, 107-112.	3.1	8
84	Impact of donor histology on survival following liver transplantation for chronic hepatitis C virus infection: A Scandinavian single-center experience. <i>Scandinavian Journal of Gastroenterology</i> , 2012, 47, 710-717.	1.5	7
85	Impact of IL28B SNPs on therapeutic outcome and liver histology differs between hepatitis C virus genotypes. <i>Pharmacogenomics</i> , 2012, 13, 847-849.	1.3	7
86	Neonatal transfusion-transmitted hepatitis C virus infection following a pre-seroconversion window-phase donation in Sweden. <i>Scandinavian Journal of Infectious Diseases</i> , 2013, 45, 796-799.	1.5	7
87	Transient and durable T cell reactivity after COVID-19. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	7.1	7
88	Predicting treatment outcome following 24 weeks peginterferon α -2a/ribavirin therapy in patients infected with HCV genotype 1: Utility of HCV-RNA at day 0, day 22, day 29, and week 6. <i>Hepatology</i> , 2007, 45, 258-259.	7.3	6
89	A Novel Fibrosis Index Comprising a Non-Cholesterol Sterol Accurately Predicts HCV-Related Liver Cirrhosis. <i>PLoS ONE</i> , 2014, 9, e93601.	2.5	6
90	Intrahepatic mRNA levels of SOCS1 and SOCS3 are associated with cirrhosis but do not predict virological response to therapy in chronic hepatitis C. <i>Liver International</i> , 2013, 33, 94-103.	3.9	5

#	ARTICLE	IF	CITATIONS
91	Cartilage oligomeric matrix protein associates with hepatic inflammation and fibrosis in hepatitis C virus infection. <i>Journal of Hepatology</i> , 2017, 67, 649-651.	3.7	5
92	Early determination of hepatitis C virus RNA may help to decide the duration of therapy for chronic hepatitis C virus genotype 2/3 infection. <i>Hepatology</i> , 2011, 53, 1067-1068.	7.3	4
93	Chronic hepatitis C in Swedish subjects receiving opiate substitution therapy—Factors associated with advanced fibrosis. <i>Scandinavian Journal of Infectious Diseases</i> , 2014, 46, 340-347.	1.5	4
94	Editorial: ribavirin continues to play a role in treatment with direct-acting antivirals for hepatitis C virus-infected patients with decompensated cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 1115-1116.	3.7	4
95	No need to discontinue hepatitis C virus therapy at the time of liver transplantation. <i>PLoS ONE</i> , 2019, 14, e0211437.	2.5	4
96	The relation of 25-hydroxy vitamin D concentrations to liver histopathology, seasonality and baseline characteristics in chronic hepatitis C virus genotype 2 or 3 infection. <i>PLoS ONE</i> , 2020, 15, e0237840.	2.5	4
97	Monitoring Virological Responses to Interferon-Ribavirin and Interferon Monotherapy of Chronic Hepatitis C Re-treated due to Relapse or Non-response. <i>Scandinavian Journal of Infectious Diseases</i> , 2001, 33, 110-115.	1.5	3
98	Impact of disease severity on outcome of antiviral therapy in treatment-naïve patients with chronic hepatitis C. <i>Hepatology</i> , 2007, 45, 1333-1334.	7.3	3
99	Observed and calculated interleukin-28B genotype frequencies in hepatitis C virus infection. <i>Hepatology</i> , 2010, 52, 1860-1861.	7.3	3
100	Do variations in the ITPA gene determine the risk of hepatitis C virus relapse?. <i>Future Microbiology</i> , 2014, 9, 1009-1012.	2.0	3
101	Hepatitis E virus genotype 3 is associated with gallstone-related disease. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 1269-1273.	1.5	3
102	Nonresponder Patients with Hepatitis C Virus Genotype 2/3 Infection: A Question of Low Systemic Interferon Concentrations?. <i>Clinical Infectious Diseases</i> , 2010, 50, e22-e25.	5.8	2
103	Reduced ITPase activity and favorable IL28B genetic variant protect against ribavirin-induced anemia in interferon-free regimens. <i>PLoS ONE</i> , 2018, 13, e0198296.	2.5	2
104	Lower risk of multiple sclerosis in patients with chronic hepatitis C: a nationwide population-based registry study. <i>Journal of Neurology</i> , 2019, 266, 2208-2215.	3.6	2
105	Monitoring treatment response by the hepatitis C virus core antigen assay. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2005, 24, 230-232.	2.9	1
106	Are FoxP3+ cells involved in hyporesponsiveness to interferon/ribavirin therapy in chronic hepatitis C?. <i>Journal of Viral Hepatitis</i> , 2011, 18, 149-151.	2.0	1
107	Dynamic tailoring of treatment durations improves efficiency of hepatitis C treatment with pegylated interferon and ribavirin. <i>Journal of Viral Hepatitis</i> , 2013, 20, e82-9.	2.0	1
108	The relationship between IFNL4 genotype and the rate of fibrosis in hepatitis C patients. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 1172-1175.	1.5	1

#	ARTICLE	IF	CITATIONS
109	Sick leave and disability pension in patients with chronic hepatitis C compared with a matched general population: a nationwide register study. <i>BMJ Open</i> , 2020, 10, e035996.	1.9	1
110	Presence of interferon- γ 4, male gender, absent/mild steatosis and low viral load augment antibody levels to hepatitis C virus. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 849-854.	1.5	1
111	Acute exacerbation of chronic hepatitis B: Yet another incentive to commence universal infant immunization even in low endemic areas. <i>Scandinavian Journal of Gastroenterology</i> , 2008, 43, 131-131.	1.5	0
112	Reply. <i>Hepatology</i> , 2014, 60, 2130-2131.	7.3	0
113	Absence of interferon- γ 4 enhances spontaneous clearance of acute hepatitis C virus genotypes 1-3 infection. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 855-861.	1.5	0